
Retatrutide, also known as LY3437943, is designed to interact with three incretin/metabolic signaling pathways: GLP-1 receptor activity, GIP receptor activity, and glucagon receptor activity. This distinguishes it from semaglutide, which targets GLP-1, and tirzepatide, which targets both GIP and GLP-1. The triple agonist framework is designed to influence appetite regulation, glucose metabolism, insulin-related signaling, and energy expenditure biology.


Videos de creadores independientes en YouTube. BioVantix no los produce ni los respalda, y no son instrucciones de uso. Se cargan desde YouTube solo al reproducirlos.